{"Symbol": "IMMU", "AssetType": "Common Stock", "Name": "Immunomedics, Inc", "Description": "Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. It also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company has clinical collaboration with AstraZeneca, MedImmune, and Roche; collaboration agreement with The Bayer Group; clinical and preclinical collaborations with academic cancer institutions; and research collaboration with the Memorial Sloan Kettering Cancer Center. It also has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody; and a collaboration and license agreement with pH Pharma Co. Ltd. for the development and commercialization of multiple novel antibody-drug conjugates in oncology. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Biotechnology", "Address": "300 The American Road, Morris Plains, NJ, United States, 07950", "FullTimeEmployees": "366", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "9682622464", "EBITDA": "-340496000", "PERatio": "None", "PEGRatio": "0", "BookValue": "2.569", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-1.631", "RevenuePerShareTTM": "0.098", "ProfitMargin": "0", "OperatingMarginTTM": "-15.3666", "ReturnOnAssetsTTM": "-0.2516", "ReturnOnEquityTTM": "-1.0004", "RevenueTTM": "20369000", "GrossProfitTTM": "-254576000", "DilutedEPSTTM": "-1.703", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "52.24", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "416.7954", "PriceToBookRatio": "15.9375", "EVToRevenue": "431.0175", "EVToEBITDA": "0", "Beta": "3.3956", "52WeekHigh": "44.91", "52WeekLow": "8.8", "50DayMovingAverage": "41.9069", "200DayMovingAverage": "29.3806", "SharesOutstanding": "231144000", "SharesFloat": "204619827", "SharesShort": "26440305", "SharesShortPriorMonth": "29431624", "ShortRatio": "15", "ShortPercentOutstanding": "0.11", "ShortPercentFloat": "0.1274", "PercentInsiders": "0.137", "PercentInstitutions": "81.313", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "2:1", "LastSplitDate": "1985-06-24"}